Research peptides and compounded peptides are not interchangeable.
A research peptide is supplied for controlled laboratory work and is not for human consumption. A compounded peptide drug is a finished preparation made by a qualifying licensed pharmacist or physician for human use under applicable compounding law. An FDA-approved peptide drug is a third category: a specific finished product reviewed by FDA for an approved indication and manufactured under the conditions in its application.
The molecules may have familiar names, but the intended use, purchaser, records, quality system, label, and regulatory pathway are different.
This distinction has become more important as searches for compounded GLP-1 vs research peptide, research use only peptides, and compounded BPC-157 have grown. It also sits behind the confusion surrounding the July 2026 FDA advisory committee peptide vote.
Research peptides vs compounded peptides at a glance
| Question | Research peptide material | Compounded peptide drug | FDA-approved peptide drug |
|---|---|---|---|
| Primary purpose | Laboratory research | A human drug prepared under applicable compounding law | Treatment under the approved labeling |
| Intended recipient | Laboratory, researcher, or qualified business | An identified patient or health-care setting, depending on pathway | Patient under the product’s approved conditions |
| Human consumption | No | Human use is the purpose | Human use is the purpose |
| Prescription or order | Research purchase specification | Usually tied to a valid prescription or lawful health-care order | Dispensed under the approved prescription or OTC framework |
| Who prepares it? | Research-material supplier or manufacturer | Qualifying licensed pharmacist, physician, or outsourcing facility | FDA-reviewed drug manufacturer |
| FDA approved? | No | No | Yes, for the specific product and use |
| Typical quality evidence | Batch identity, purity, content, and other requested research specifications | Finished-preparation quality, strength, microbial controls, sterility/endotoxin where applicable, and pharmacy records | Application-supported identity, strength, quality, purity, potency, manufacturing controls, and postmarket obligations |
| Labeling focus | Research use only; not for human consumption | Patient, prescriber, directions, strength, route, beyond-use and required pharmacy information | FDA-approved labeling |
The table is a map, not legal advice. U.S. compounding law has detailed federal and state requirements, and the facts of a specific activity matter. But one rule is reliable: do not use the three categories as synonyms.
What is a research peptide?
A research peptide is a chemical or biological reference material intended for laboratory investigation. The customer may use it in analytical method development, assay work, comparative studies, cell models, or other controlled research.
The purchasing record should describe the research material as a material:
- exact peptide name and chemical form;
- sequence or molecular information when relevant;
- lyophilized, solution, or bulk format;
- stated mass or concentration;
- batch or lot number;
- storage and handling requirements;
- test methods and acceptance criteria; and
- the current batch COA or laboratory report.
Certiva supplies peptide reference materials for laboratory research use only. They are not medicines, are not supplied for self-administration, and are not substitutes for a prescription or pharmacy-prepared drug.
The phrase “research peptide” describes intended use. It does not mean every research material has the same grade, specification, or testing package. One buyer may need HPLC purity and mass-spectrometry identity. Another project may also specify content, water, counterion, residual solvents, or microbiological limits. The required evidence should follow the documented research protocol.
What is a compounded peptide?
Drug compounding generally involves combining, mixing, or altering ingredients to create a medication for a patient’s clinical need. FDA explains that compounding can serve an important role when a patient’s needs cannot be met by an FDA-approved drug—for example, when a needed formulation is unavailable or an ingredient must be omitted.
In the United States, two federal pathways are commonly discussed:
- Section 503A primarily addresses qualifying patient-specific compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician.
- Section 503B addresses registered outsourcing facilities that meet applicable conditions and additional federal oversight requirements.
A bottle or vial does not become a compounded drug merely because a website uses the word “compounded.” The identity and licensing of the preparer, prescription or order basis, bulk-substance eligibility, facility obligations, labeling, state law, and actual distribution model all matter.
Are compounded peptides FDA approved?
No.
FDA’s consumer explanation of compounded-drug risks states that compounded drugs are not FDA approved. The agency does not conduct premarket review of each compounded product for safety, effectiveness, or quality.
That does not mean every compounded drug is unlawful or unnecessary. It means compounded and FDA approved are different regulatory descriptions.
The distinction also prevents another common error: a compounded product is not an FDA-approved generic. FDA-approved generics must meet approval requirements concerning the approved reference product. A compounded preparation has not gone through that generic-drug approval process.
What is an FDA-approved peptide drug?
An FDA-approved drug is a specific finished product supported by an application. FDA evaluates evidence for the proposed use and reviews manufacturing information, quality controls, and labeling.
Approval attaches to the product and its conditions of use—not to every vial, powder, salt form, blend, or online listing that shares part of the ingredient name.
This is especially important for GLP-1 products. An FDA-approved semaglutide product does not make every product described as “semaglutide” approved, equivalent, or generic. The finished product, manufacturer, formulation, labeling, and approved application matter.
Does “research use only” decide the category by itself?
No. The label is important, but the complete intended-use evidence matters.
A legitimate RUO label should be consistent with the whole transaction:
- the website avoids treatment, dosage, and patient-result claims;
- the seller does not direct consumers to self-administer the material;
- the inquiry and invoice describe research specifications;
- the buyer has a plausible laboratory or business research purpose;
- packaging and documentation are consistent with research use; and
- customer support does not quietly provide human-use instructions.
FDA warning letters to peptide sellers show why the surrounding claims matter. For example, the agency has cited websites whose products carried research-style disclaimers while other pages promoted effects on diseases, injuries, weight, or human physiology.
A footer saying “not for human consumption” does not cancel contradictory human-use marketing. Conversely, a carefully controlled research sale is not a pharmacy prescription simply because the material name also appears in medical research.
Compounded GLP-1 vs research peptide: why the difference matters
GLP-1 names now appear across approved medicines, compounded-drug advertising, clinical trials, and research catalogs. That creates a high risk of category confusion.
Semaglutide and tirzepatide
FDA-approved finished products containing semaglutide or tirzepatide exist. Compounded versions are not FDA approved, even when a prescriber determines that a compounded drug is appropriate for a patient and the compounder operates under an applicable pathway.
FDA’s updated concerns about unapproved GLP-1 drugs include dosing errors, adverse-event reports, misleading claims, and semaglutide salt forms that differ from the active ingredient used in approved drugs.
Research semaglutide or tirzepatide is yet another category. It is material for a laboratory project, not a lower-cost patient version of an approved medicine.
Retatrutide and cagrilintide
As of this article’s publication date, FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law. FDA also notes that they are not components of FDA-approved drugs and have not been found safe and effective for any condition.
That makes phrases such as “compounded retatrutide prescription” a major diligence signal. A research supplier may offer retatrutide as an RUO reference material, but that does not create a compounding pathway or authorize human treatment.
Readers following the clinical pipeline can use our retatrutide Phase 3 results guide for a study-focused explanation that distinguishes trial findings from research-material availability.
Does a COA prove the same thing in every category?
No.
A COA only supports the tests, sample, and batch shown on the document. The title “Certificate of Analysis” does not create a universal test package.
For a research peptide, a useful core report often includes:
- sample and batch identification;
- HPLC or another appropriate purity method;
- mass-spectrometry or other identity confirmation;
- content or assay when specified;
- dates, methods, results, and authorization; and
- a clear connection to the material being shipped.
For a finished sterile compounded preparation, the quality questions extend further. Depending on the dosage form and applicable requirements, the pharmacy may need to address:
- finished-product strength;
- sterility;
- bacterial endotoxins;
- particulate matter;
- microbial and environmental controls;
- container-closure suitability;
- beyond-use dating and stability support; and
- preparation, dispensing, and traceability records.
A 99% HPLC purity result does not prove sterility, and a sterility result does not confirm molecular identity or labeled strength. Our guide to peptide purity vs sterility vs endotoxin shows which question each test answers.
Five questions to identify what is actually being offered
When a listing uses words such as peptide, compound, pharmaceutical, clinical, medical grade, or pharmacy grade, ask these five questions.
1. What is the intended use?
Is the product offered for a laboratory protocol or for an identified patient’s treatment? If the answer changes depending on which page or sales representative you ask, stop.
2. Who is the seller and preparer?
Record the legal entity, facility, location, licenses, and role. A raw-material supplier, research supplier, licensed pharmacy, outsourcing facility, clinic, and FDA-approved manufacturer are not interchangeable.
3. What document authorizes the transaction?
A research order should have a material specification and research purpose. A patient drug should have the appropriate prescription or health-care order and pharmacy documentation.
4. What exact product and batch will be supplied?
Ask for the peptide form, composition, strength, dosage form, batch number, and current reports. Do not assume that a report for raw API describes a finished vial.
5. Which claims are being made?
“High purity,” “sterile,” “FDA approved,” “generic,” “same active ingredient,” and “clinically proven” are different claims. Each needs its own evidence and legal basis.
A practical document checklist for research buyers
For an RUO peptide inquiry, send the same structured request to every supplier:
- peptide name and exact form;
- required quantity and format;
- target purity and identity methods;
- content or assay requirement;
- any project-specific additional tests;
- current-batch COA;
- packaging and storage requirements;
- delivery country and timeline; and
- confirmation that the material is for laboratory research only.
Then compare like with like. A low quote for an unnamed form with a generic report is not comparable to a batch-specific offer with defined methods and results.
Use our peptide RFQ template to turn that list into a quote-ready request, and review the peptide supplier audit checklist before approving a new source.
Red flags that the categories are being blurred
Pause when you see:
- an RUO product page with dosage or self-administration instructions;
- a compounded product called “FDA approved” or “generic” without an approved application;
- a research supplier claiming its COA makes a vial safe for injection;
- a medical seller with no identifiable licensed pharmacy or prescriber pathway;
- a raw-material report presented as proof of finished-product sterility;
- retatrutide or cagrilintide marketed as a routine compounded prescription;
- an “FDA registered” claim used as if registration were product approval; or
- the same report used across different forms, strengths, or batches.
These red flags do not all prove the same violation. They tell the buyer that the seller has not made the product category and evidence trail clear.
The intended use changes the entire pathway
Research peptides are for laboratory work. Compounded peptides are patient-focused preparations made under applicable compounding law. FDA-approved peptide drugs are specific products reviewed through an approval application.
The shared molecule name is not enough to cross from one category to another.
For research procurement, keep the transaction in the research lane: define the material, match the batch, review the actual methods and results, document the research purpose, and avoid human-use claims.
Certiva supplies research reference materials with batch documentation for qualified laboratory and business inquiries. All peptide materials are for research use only and are not for human consumption.
Request a research specification, current-batch COA and quote →
Sources and further reading
- FDA: Understanding the Risks of Compounded Drugs
- FDA: Is It Really “FDA Approved”?
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA: Bulk Drug Substances Used in Compounding Under Section 503A
- FDA warning letter: Summit Research Peptides
- FDA warning letter: USApeptide.com
Frequently asked questions
What is the difference between research peptides and compounded peptides?
Research peptides are materials supplied for controlled laboratory work and not for human consumption. Compounded peptides are finished preparations made by a qualifying licensed pharmacist or physician for human use under applicable compounding law. They have different intended uses, buyers, records, labels and quality requirements.
Are compounded peptides FDA approved?
No. FDA states that compounded drugs are not FDA approved and do not undergo FDA premarket review for safety, effectiveness or quality. They may serve an important patient need when applicable legal conditions are met, but they are not generic or approved versions of brand-name drugs.
Does a research use only label make a peptide legal for human use?
No. A research use only label communicates that a material is not intended for human use. It does not authorize treatment, prescribing or administration, and wording alone cannot override marketing claims or conduct showing that a product is intended for people.
Is a peptide COA the same as a pharmacy sterility report?
No. A typical research-material COA may report identity, HPLC purity and content for a batch. Sterility, bacterial endotoxins, potency of a finished preparation, container-closure integrity and beyond-use dating are separate questions that require appropriate methods and records.
Can retatrutide be compounded?
FDA currently states that retatrutide and cagrilintide cannot be used in compounding under federal law. Retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Is compounded semaglutide the same as FDA-approved semaglutide?
No. A compounded semaglutide preparation is not an FDA-approved generic and should not be represented as the same as an FDA-approved product. FDA has also raised concerns about salt forms, dosing errors, adverse events and misleading marketing involving unapproved GLP-1 products.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More quality testing & COAs guides · Have a question? Start an inquiry →